Latest Thrombus Stories

RESEARCH TRIANGLE PARK, N.C., June 11, 2012 /PRNewswire/ -- Grifols, a global healthcare company based in Barcelona, Spain, today announced publication of phase 1 study results demonstrating good safety and tolerability for the investigational therapy plasmin in treating patients with blood clots in the lower extremities, known as acute peripheral arterial occlusion (aPAO). These clots can block blood flow and thus result in nerve damage, limb amputation or potentially loss of life...

According to court documents, on May 15th 2012, a Massachusetts woman, Janel Mahon, filed a lawsuit in Illinois Southern District Court (case no. 3:2012cv10881) alleging she suffered blood clots leading to a pulmonary embolism from Yaz. Yasmin, which was approved by the FDA in 2001, and its sister drug Yaz, which was approved in 2006, are oral contraceptives that combine estrogen and a fourth generation progestin, drospirenone, to prevent pregnancy. Yaz and Yasmin are manufactured by Bayer...

[ Watch the Video ] Mice and monkeys don't develop diseases in the same way that humans do. Nevertheless, after medical researchers have studied human cells in a Petri dish, they have little choice but to move on to study mice and primates. University of Washington bioengineers have developed the first structure to grow small human blood vessels, creating a 3-D test bed that offers a better way to study disease, test drugs and perhaps someday grow human tissues for transplant. The...

Patients more likely to have blood flow in blocked artery fully restored Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes Online First doi 10.1136/neurintsurg-2011-010245 Treatment is faster and outcomes are better at stroke centers dealing with a high volume of patients, finds research published online in the Journal of NeuroInterventional Surgery. The authors base their findings on 442...

Research findings offer a new direction for a therapeutic agent to prevent stroke, heart attack A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis. These new findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and published in today's on-line issue of The Journal of Clinical Investigation (JCI), identify a...

UD researchers discover that JAM-A protein keeps blood clots in check Cut your toe, and platelets -- those disc-shaped cells circulating in your blood  -- rush to the scene, clumping together to plug the leak. But when an unwanted clot forms in an artery, and an overaccumulation of platelets blocks blood flow, a heart attack or stroke occurs, too often with fatal results. Heart disease and stroke rank as humankind’s top killers, according to the World Health Organization. Ulhas...

Having a virtual copy of a patient’s blood in a computer would be a boon to researchers and doctors. They could examine a simulated heart attack caused by blood clotting in a diseased coronary artery and see if a drug like aspirin would be effective in reducing the size of such a clot. Now, a team of biomedical engineers and hematologists at the University of Pennsylvania has made large-scale, patient-specific simulations of blood function under the flow conditions found in blood...

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging Science Series webinar. Patients with certain types of atrial fibrillation, or irregular heartbeat, take these drugs to reduce the risks of clots that could lead to a stroke. Sometimes they are instructed to stop taking the medication temporarily before surgery or...

SILVER SPRING, Md., April 16, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS will be an official exhibitor at the Thrombosis and Hemostasis Summit of North America (the "THSNA") to be held May 3-5, 2012 at the Hyatt Regency Chicago. "Participation as an official exhibitor at this year's THSNA...

Study finds new treatment approach could benefit hundreds of thousands per year Pulmonary embolism -- the sudden blockage of an artery in the lung -- is estimated to cause over 100,000 deaths each year in the U.S. Although thrombolytics, or "clot-buster" drugs, are currently reserved to treat only the most severe cases of pulmonary embolism, new data suggest that when used at lower doses, these drugs are also safe and effective for more common, moderate cases of pulmonary embolism,...